MoonLake Immunotherapeutics Class A MLTX 深 滬
已收盤 02-06 16:00:00 美东时间
15.51
+0.740
+5.01%
華盛通- 最 高15.62
- 今 開14.90
- 成交量 86.17万股
- 最 低 14.825
- 昨 收 14.77
- 總市值 11.15亿
- 52周最高 62.75
- 市盈率 靜 --
- 換手率 1.20%
- 52周最低 5.95
- 委 比 4.57%
- 總股本 7189.98万
- 歷史最高 64.98
- 量 比 0.64
- 振 幅 5.38%
- 歷史最低 4.25
- 每 手 1
- 風險率 16.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅213.87%！Wave Life Sciences获Canaccord Genuity升目标价至43美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Wave Life Sciences Ltd."买入"评级，目标价从40美元升至43美元；花旗：维持Palantir Technologies"买入"评级，目标价从235美元升至260美元
02-04 12:15
Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case
Avalo Therapeutics completed Phase 2 enrollment for AVTX-009, with mid-2026 data ahead. Cantor sees major upside if results impress, but warns shares could plunge if the trial disappoints.
02-03 03:25
MoonLake Immunotherapeutics Announces FDA Grants Fast Track Designation For Sonelokimab To Treat Moderate‑To‑Severe Palmoplantar Pustulosis
MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces that the FDA has granted
02-02 21:02
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
MoonLake Immunotherapeutics announced that the FDA has granted Fast Track designation to sonelokimab (SLK) for the treatment of moderate-to-severe palmoplantar pustulosis (PPP), supported by positive results from the Phase 2 LEDA trial. This designation will facilitate the development and expedite the review of SLK, enabling more frequent interactions with the FDA and potentially faster approval.MoonLake also confirmed plans to submit a Biologic ...
02-02 13:00
美股大行评级 | 阿斯麦、美光科技、SanDisk获大行上调目标价；美国银行、富国银行绩后遭多家机构下调目标价
今日重点评级关注：Benchmark：维持TNL Mediagene"投机性买入"评级，目标价从3.5美元升至14美元；康托·菲茨杰拉德：维持Eupraxia Pharmaceuticals"超配"评级，目标价从11美元升至19美元
01-16 10:04
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
BTIG Upgrades MoonLake to Buy, Announces $24 Price Target
BTIG analyst Julian Harrison upgrades MoonLake (NASDAQ:MLTX) from Neutral to Buy and announces $24 price target.
01-09 18:58
美股牛股 | 获FDA支持加速药物上市！MoonLake大涨27%；Satellogic大涨21.7%
获FDA支持加速药物上市！MoonLake大涨27%；宣布获七位数地球观测合同，Satellogic涨超21%>>
01-09 16:01
MoonLake Immunotherapeutics shares are trading higher after the company said FDA feedback confirmed it may establish substantial evidence of effectiveness for hidradenitis suppurativa without additional clinical trials.
MoonLake Immunotherapeutics shares are trading higher after the company said FD...
01-08 21:27
MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day
MoonLake Immunotherapeutics requested a Type B meeting with the FDA to discuss the clinical evidence strategy for its Sonelokimab (SLK) in Hidradenitis Suppurativa (HS). The FDA confirmed that MoonLake can establish substantial evidence of effectiveness (SEE) without additional clinical trials, using data from its existing VELA-1, VELA-2, and MIRA trials. MoonLake plans to submit a BLA for SLK in HS in H2 2026. An Investor Day will be held on Feb...
01-08 13:00
